August 8, 2025 — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company specializing in gene therapies for blindness diseases, announced it has entered into a securities purchase agreement with Janus Henderson Investors to purchase 20,000,000 shares of common stock and warrants to purchase up to 20,000,000 shares of common stock at $1.00 per share and accompanying warrant in a registered direct offering.
The warrants have an exercise price of $1.50 per share, are exercisable immediately, and expire two years following issuance. The warrants are callable by the Company when the VWAP of the Company’s common stock exceeds $2.50 per share for at least five of a trailing 30 trading day period.
Noble Capital Markets, Inc. is acting as the sole placement agent for the offering. The gross proceeds to the Company are expected to be approximately $20 million before deducting fees. The Company may receive up to $30 million of additional gross proceeds if the warrants are exercised in full. The offering is expected to close on or about August 11, 2025, subject to closing conditions.
The offering is made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-278774) previously filed with the SEC. Copies of the prospectus supplement can be obtained at www.sec.gov or from Noble Capital Markets, Inc., 150 East Palmetto Park Rd., Suite 110 Boca Raton, FL 33432.
Ocugen Contact:
Tiffany Hamilton
AVP, Head of Communications
Tiffany.Hamilton@Ocugen.com
Source: Ocugen, Inc.
